Galectin Therapeutics reports positive DSMB outcome for NAVIGATE study of belapectin in NASH cirrhosis

GALECTIN THERAPEUTICS INC

Second DSMB meeting recommends study continue as designed without modifications.
NAVIGATE is a seamless adaptive Phase 2b/3 trial of belapectin for primary prevention of esophageal varices in NASH cirrhosis.
Enrollment: 258 patients randomized; 74 in screening; full enrollment expected around year-end 2022.
DSMB confirms belapectin appears safe and well tolerated in fragile cirrhotic patients.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.